Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy.

@article{Got2011IrinotecanAT,
  title={Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy.},
  author={Akira Gotō and Yasutaka Sukawa and Hisayoshi Igarashi and Kei Onodera and Yuka Aoki and Kazuya Suzuki and Kazuhiko Yonezawa and Atsushi Yawata and Toshihisa Kobayashi and Hiroyuki Kaneto and Haruo Shimizu and Hideki Wakasugi and Yasutaka Matsunaga and Miki Itoh and Hiroyuki Okuda and Yoshiaki Arimura and Yasuhisa Shinomura},
  journal={Gan to kagaku ryoho. Cancer & chemotherapy},
  year={2011},
  volume={38 9},
  pages={
          1461-6
        }
}
BACKGROUND S-1, an oral fluoropyrimidine, is one of the standard chemotherapeutic agents for the treatment of metastatic gastric cancer(MGC). However, the most effective second-line regimen after failure of treatment with first-line agents such as S-1 is yet to be determined. The aim of this study was to investigate the various second-line chemotherapy regimens in MGC patients. METHODS We retrospectively studied patients with MGC who received second-line treatment after failure of the first… CONTINUE READING